Postby DK37 » Thu Jun 16, 2016 3:46 pm
The Cobi (MEK inhibitor) + Atezo (PDL1 immunotherapy) randomized Phase 3 trial has opened at least one site for recruitment (Washington State):
Medical Oncology Associates
6001 N. Mayfair Street
Spokane, WA. 99208
Chris Weber, Study Coordinator
Monika Chaudhry, Intake Screening
(509) 462-2273
https://clinicaltrials.gov/ct2/show/NCT ... 279&rank=1
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
7/12 FOLFOX/FOLFIRI
2/13 NED!
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
3/15 Cetuximab
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)
MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List